Amicus Therapeutics — Investor Presentation (May 2020)
43 slides from Amicus Therapeutics's investor presentation, May 14, 2020
Slide 1: General Corporate & Gene Therapy Overview
General Corporate & Gene Therapy Overview: At the Forefront of the Human Genome Medicine Revolution May 2020
Slide 2: Forward-Looking Statements
General Corporate & Gene Therapy Overview 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporti
Slide 3: A leading fully-integrated, global rare disease biotechnology company
General Corporate & Gene Therapy Overview 3 PLATFORM & Glycobiology AT-GAA Phase 3 in Pompe Disease Two Clinical-Stage Gene Therapies $338M+ Cash as of 3/31/20 GLOBAL COMMERCIAL ORGANIZATION Robust R&D Engine Nearly 50+ Lysosomal Disorders and More Prevalent Rare Diseases EMPLYEES in 27ountries Gene
Slide 4: Key Takeaways
General Corporate & Gene Therapy Overview 4 Key Takeaways Strong Financial Outlook with Current Cash Well into 2H2022 Portfolio of Gene Therapy Programs and Technologies Provides Foundation for Future AT-GAA for Pompe Advances Toward Approval as “Crown Jewel” of Amicus Portfolio Galafold Continues S
Slide 5: Pipeline by franchise and development phase
General Corporate & Gene Therapy Overview 5 Disease Designation *Exclusive license from Ultragenyx for Japanese rights to Mepsevii™, investigator-sponsored trial in Japan underway DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) Monotherapy Fabry Ge
Slide 6: Galafold Global Launch
Galafold®(migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 7: Galafold Snapshot (as of March 31, 2020)
General Corporate & Gene Therapy Overview 7 Galafold Snapshot (as of March 31, 2020) One of the Most Successful $250-260M FY20 Global $60.5M 1Q20 R Rare Disease Launches nce Continue Expansio in 2020 348 ble Variants in U.S. Label 40+ Countries with Regulatory Approvals: Including U.S., EU, Japan, a
Slide 8: Galafold Quarterly Performance
General Corporate & Gene Therapy Overview 8 Galafold Quarterly Performance Quarterly Galafold Sales Year-over-Year Galafold Sales Growth $60.5M 1Q19 2Q19 3Q19 4Q19 1Q20 1Q19 Operational Growth FX Impact 1Q20 1Q19 vs 1Q20 $55M $49M $44M $34M -3% $60.5M $34M +81% Quarterly Growth Remains Steady with 1
Slide 9: Galafold Growth Trajectory
General Corporate & Gene Therapy Overview 9 Galafold Growth Trajectory $1B Annual Revenue $500M+ $250M-$260M $91M $182M FY18 FY19 FY20 FY21 ~$1B FY22 FY23 Peak Projected Cumulative Revenues (2020-2022) Galafold is on track to generate $1B+ in projected cumulative revenues from 2020-2022 and is on an
Slide 10: Global Supply Chain
General Corporate & Gene Therapy Overview 10 Global Supply Chain Galafold Carbogen, Switzerland Existing Supply Chain Strategy: • Galafold: Hold multiple years of inventory in API and Drug Product • AT-GAA: Built inventory ahead of time and move drug product to UK AT-GAA Wuxi, China AL M AC C L IN I
Slide 11: AT-GAA: Next Potential Standard of Care for Pompe Disease
AT-GAA:Next Potential Standardof Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 12: Pompe Disease Overview
General Corporate & Gene Therapy Overview 12 Pompe Disease Overview 5,000 – 10,000+ patients diagnosed WW1; newborn screening suggests underdiagnosis Respiratory and cardiac failure are leading causes of morbidity and mortality Age of onset ranges from infancy to adulthood Patients on current standa
Slide 13: AT-GAA: Foundation in Protein Engineering
General Corporate & Gene Therapy Overview 13 AT-GAA: Foundation in Protein Engineering Amicus scientists specializing in protein engineering and glycobiology created a uniquely glycosylated and highly phosphorylated ERT (AT-GAA) that significantly enhances targeting to key muscles affected in patien
Slide 14: U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease
General Corporate & Gene Therapy Overview 14 U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) AT-GAA BTD Based on Ph 1/2 Clinical Efficacy • • Improvements in 6-minute walk distance Comparison to natural history of treated patients Plans to initiate a rolling BLA submission for AT-G
Slide 15: Pompe Patient Experience in Phase 1/2 Clinical Study
General Corporate & Gene Therapy Overview 15 Pompe Patient Experience in Phase 1/2 Clinical Study (ATB200-02) (n=10a) Mean (SD) (n=10a) Mean (SD) (n=9a,b) Mean (SD) (n=5) Mean (SD) (n=5) Mean (SD) (n=5) Mean (SD) (n=9c) Mean (SD) (n=9c) Mean (SD) (n=8b,c) Mean (SD) (n=5) Mean (SD) (n=5) Mean (SD) (n
Slide 16: 6MWT Natural History: Phase 1/2 AT-GAA Data vs. Medical Literature (van der Ploeg 2017)
General Corporate & Gene Therapy Overview 16 6MWT Natural History: Phase 1/2 AT-GAA Data vs. Medical Literature van der Ploeg 2017 Comparison of Phase 1/2 AT-GAA data to Natural History on Standard of Care: ATB200-02 Versus van der Ploeg 2017 Study 40 20 AT-GAA 0 -20 Standard of Care -40 -60 N (Lots
Slide 17: 6MWT Natural History: Phase 1/2 AT-GAA Data vs. Medical Literature (Masat 2016)
General Corporate & Gene Therapy Overview 17 6MWT Natural History: Phase 1/2 AT-GAA Data vs. Medical Literature Masat 2016 Change from Baseline in Percent Predicted 6MWT as a Function of Baseline in Subjects Treated with ERT for 2+ Years: ATB200-02 Versus Masat 2016 Study 40 AT-GAA 20 0 -20 Standard
Slide 18: PROPEL (ATB200-03) Study Design
General Corporate & Gene Therapy Overview 18 PROPEL (ATB200-03)Study Design 52-Week Primary Treatment Period (Double-Blind) 2:1 Randomization • PROPEL pivotal study over-enrolled with data expected in 1H2021 AT-GAA Bi-Weekly Participants with Late-Onset Pompe Disease n=123 59 WW Clinical Sites • Stu
Slide 19: AT-GAA: Key Takeaways
General Corporate & Gene Therapy Overview 19 AT-GAA: Key Takeaways • PROPEL study timelines are on track with data expected 1H2021 – To date, 97% of the 2,250 planned infusions for the ongoing PROPEL study have been completed on schedule • Breakthrough Therapy Designation and the Promising Innovativ
Slide 20: Next Generation Gene Therapy Platform
Next GenerationGene TherapyPlatform “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 21: A Natural Evolution: Chaperones to Optimized ERT to Gene Therapy
General Corporate & Gene Therapy Overview 21 A Natural Evolution: Chaperones to Optimized ERT to Gene Therapy Pharmacological Chaperones Next-Generation ERTs Gene Therapies Stabilize “naturally produced” enzymes Stabilize and target “externally produced” enzymes Stabilize and target “internally prod
Slide 22: Validated Gene Therapy Platform for CNS
General Corporate & Gene Therapy Overview 22 Validated Gene Therapy Platform for CNS Clinically validated AAV gene therapy approach at NCH and Sanford – Nationwide Children’s Hospital Center for Gene Therapy (NCH) – Intrathecal delivery with robust expression throughout CNS Preclinical safety and ef
Slide 23: Batten Disease Overview
General Corporate & Gene Therapy Overview 23 Batten Disease Overview Source: Batten Disease Fact Sheet, NINDS, Publication date June 2018. Disease Overview •A group of disorders known as neuronal ceroid lipofuscinoses (NCLs), collectively referred to as Batten disease •Mutation in one of 13 differen
Slide 24: CLN6 Natural History
General Corporate & Gene Therapy Overview 24 CLN6 Natural History n=11 pts with late-infantile CLN6 Age (months) Source: Data on file: Ongoing Natural History study conducted by Nationwide Children’s Hospital and Dr. Emily de los Reyes Mean Hamburg Motor + Language Score CLN6 natural history shows a
Slide 25: Clinical Efficacy: Combined and Individual Hamburg Scores
General Corporate & Gene Therapy Overview 25 Clinical Efficacy: Combined and Individual Hamburg Scores (n=8) Patient 6 Treated at 56 Months Patient 3 Treated at 36 Months Patient 2 Treated at 30 Months Patient 7 Treated at 19 Months 6 5 4 3 2 1 0 6 5 4 3 2 1 0 6 5 4 3 2 1 0 6 5 4 3 2 1 0 0 3 6 9 12
Slide 26: CLN6 Clinical Efficacy Data: Sibling Comparisons
General Corporate & Gene Therapy Overview 26 CLN6 Clinical Efficacy Data: Sibling Comparisons (Natural History) Treated AAV-CLN6 Patients vs Natural History Sibling with CLN6 (Hamburg Score: Motor + Language over time) Treated Patient 3 vs. Untreated Sibling Treated Patient 6 vs. Untreated Sibling T
Slide 27: CLN6 Clinical Efficacy Data: Natural History Matched Comparisons
General Corporate & Gene Therapy Overview 27 CLN6 Clinical Efficacy Data: Natural History Matched Comparisons N= 4 NH pts N= 9 NH pts N= 3 NH pts Age (months) Age (months) Age (months) Age (months) GTx patient NH Pts (mean) N= 1 NH pt N= 1 NH pt N= 1 NH pt N= 4 NH pts Age (months) Age (months) Age (
Slide 28: CLN3 Batten Disease: Preclinical and Clinical Summary
General Corporate & Gene Therapy Overview 28 CLN3 Batten Disease: Preclinical and Clinical Summary Preclinical Data in KO Mice Reduction of storage material in mouse model Improvement of motor function and cognitive behavior in mouse model Comparable survival mouse model in Widespread gene expressio
Slide 29: Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases
General Corporate & Gene Therapy Overview 29 Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases Protein Engineering & Glycobiology Expertise Clinical and Regulatory Expertise Global Commercial Infrastructure Team of 200+ scientists bringing expertise and experience in: Vectors, Tr
Slide 30: Engineered Transgenes for Optimal Cross-Correction
General Corporate & Gene Therapy Overview 30 Amicus Approach: Engineered Transgenes for Optimal Cross-Correction (4) Proteins include targeting moieties for improved uptake Transgene encapsulated in AAV Target protein enters target cell via receptor binding DNA (transgene) Modified AAV injected into
Slide 31: Protein Engineering Platform Broadly Applicable to LSDs
General Corporate & Gene Therapy Overview 31 Protein Engineering Gene Therapies For Platform Has Potential To Be Broadly Applicable to Majority of LSDs Pompe - GAA CLN1 – PPT1 CLN2 – TTP1 3 60 30 2 40 20 1 20 10 0 0 0 0 2 4 6 8 10 0.0 0.5 1.0 0.0 0.1 0.2 0.3 0.4 0.5 rhGAA (nM) Relative concentration
Slide 32: Initial Preclinical Pompe Gene Therapy Results: CNS
General Corporate & Gene Therapy Overview 32 Initial Preclinical Pompe Gene Therapy Results: CNS Vehicle AAV.hGAA nat AAV.hGAA eng Wild-Type Gaa -/-Gaa -/-Gaa +/+ Gaa -/-▪ Similar results observed in brain Source: Molecular Therapy Vol 27 No 4S1 April 2019, Abstract 518 Spinal cord Score 20X Spinal
Slide 33: New Pompe Gene Therapy Low Dose Preclinical Data
General Corporate & Gene Therapy Overview 33 New Pompe Gene Therapy Low Dose Preclinical Data Vehicle AAV.hGAA eng AAV.hGAA nat Normal mouse 5 4 3 2 1 0 ▪ Similar design as high dose preclinical study Source: Data on file Vehicle AAV.hGAA nat AAV.hGAA eng Normal Quadriceps: Glycogen PAS Quadriceps:
Slide 34: GTx Manufacturing Strategy for Initial Penn Programs at Catalent
General Corporate & Gene Therapy Overview 34 GTx Manufacturing Strategy for Initial Penn Programs at Catalent GENE THERAPY Long-term supply agreements established for research and GMP quality plasmids Penn is supporting technology transfer of existing manufacturing process to Catalent Technologies a
Slide 35: Gene Therapy: Updates & Key Takeaways
General Corporate & Gene Therapy Overview 35 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 1/2 interim data show profound impact with potential to become first ever approved gene therapy for fatal brain disease in children Additional patients to be dosed in Phase 1/2 study of CLN3 in 2021 with
Slide 36: Financial & Operational Strategy
Financial & Operational Strategy “We are business led and science driven” - Amicus Belief Statement
Slide 37: Financial Outlook: Key Takeaways
General Corporate & Gene Therapy Overview 37 Financial Outlook: Key Takeaways • Cash runway now well into 2H2022 – Achieved through continued careful expense management, prioritization of very early stage research programs and more measured capital expenditures • Non-GAAP quarterly operating expense
Slide 38: Financial Summary & Guidance
General Corporate & Gene Therapy Overview 38 Financial Summary & Guidance Cash ~$338M+ Cash Runway1 Well Into 2H2022 Debt1,2 $152.8M 257,449,995 Shares Outstanding (as of 3/31/2020) $250M-$260M $410M-$420M FY20 Galafold Revenue Guidance FY20 Non-GAAP Operating Expense Guidance 1Based on existing ope
Slide 39: Cash Runway Now to Well into 2H2022
General Corporate & Gene Therapy Overview 39 Cash Runway Now to Well into 2H2022 (~2+ years) $338M+ Cash 1Q2020 Well into ~2+ Years Cash Runway 2H2022 Fully funded through major milestones in portfolio and continued global growth
Slide 40: At Major Inflection Point: Path to Profitability
General Corporate & Gene Therapy Overview 40 At Major Inflection Point: Path to Profitability • • • • • Grow Galafold Advance AT-GAA to pivotal data, global approvals and launch Progress CLN6, CLN3 and Pompe gene therapies into and through the Generate 1-2 gene therapy INDs every year starting in 20
Slide 41: Our Passion for Making a Difference Unites Us
General Corporate & Gene Therapy Overview 41 Our Passion for Making a Difference Unites Us Amicus is now at a major inflection point and positioned to create significant shareholder value ahead while advancing our mission for patients.
Slide 42: Appendix
Appendix
Slide 43: Reconciliation of Non-GAAP Financial Measures
Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended March 31, 2020 2019 s Total operating expenses - as reported GAAP Research and development: Share-based compensation Selling, general and administrative: Share-based compensation Changes illfair
Amicus Therapeutics — Investor Presentation (May 2020) on 6ix